DE69930619D1 - Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen - Google Patents

Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen

Info

Publication number
DE69930619D1
DE69930619D1 DE69930619T DE69930619T DE69930619D1 DE 69930619 D1 DE69930619 D1 DE 69930619D1 DE 69930619 T DE69930619 T DE 69930619T DE 69930619 T DE69930619 T DE 69930619T DE 69930619 D1 DE69930619 D1 DE 69930619D1
Authority
DE
Germany
Prior art keywords
immunosuppressor
inhibitor
derivatives
mediated processes
rosmaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69930619T
Other languages
English (en)
Other versions
DE69930619T2 (de
Inventor
Mi Hur
Bong Choi
Changwon Park
Jongsung Lee
Dongsu Park
Yungdae Yun
Hyeung Lee
Jong-Eun Oh
Choul Ahn
Sun Lee
Sok Ahn
Il Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Biotechnology Research Institute
Original Assignee
Mogam Biotechnology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980017741A external-priority patent/KR100279902B1/ko
Priority claimed from KR1019990015989A external-priority patent/KR20000072988A/ko
Application filed by Mogam Biotechnology Research Institute filed Critical Mogam Biotechnology Research Institute
Publication of DE69930619D1 publication Critical patent/DE69930619D1/de
Application granted granted Critical
Publication of DE69930619T2 publication Critical patent/DE69930619T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69930619T 1998-05-16 1999-05-12 Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen Expired - Fee Related DE69930619T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR9817741 1998-05-16
KR1019980017741A KR100279902B1 (ko) 1998-05-16 1998-05-16 하고초로부터 분리된 림프구 세포 카이나아제의 에스에이치2 영역에 대한 결합 저해활성을 갖는 로즈마린산 및 그 분리정제방법
KR9915989 1999-05-04
KR1019990015989A KR20000072988A (ko) 1999-05-04 1999-05-04 로즈마린산 및 그 유도체의 면역억제제 또는 ｓｈ２ 억제제로서의 용도
PCT/KR1999/000232 WO1999059606A1 (en) 1998-05-16 1999-05-12 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process

Publications (2)

Publication Number Publication Date
DE69930619D1 true DE69930619D1 (de) 2006-05-18
DE69930619T2 DE69930619T2 (de) 2006-12-28

Family

ID=36274112

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930619T Expired - Fee Related DE69930619T2 (de) 1998-05-16 1999-05-12 Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen

Country Status (7)

Country Link
US (1) US6140363A (de)
EP (1) EP1077715B1 (de)
JP (1) JP3827948B2 (de)
CN (1) CN1219509C (de)
AU (1) AU3734999A (de)
DE (1) DE69930619T2 (de)
WO (1) WO1999059606A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062365A1 (fr) * 2001-02-01 2002-08-15 Meiji Seika Kaisha, Ltd. Procede de production d'un extrait vegetal de lamiacee contenant des phenols, et utilisation de ce dernier
US20030099725A1 (en) * 2001-02-26 2003-05-29 Global Cancer Strategies Ltd. Herbal compositions useful as chemopreventive and therapeutic agents and methods of manufacturing same
KR100483707B1 (ko) 2001-05-18 2005-04-18 에스케이케미칼주식회사 관절 보호용 생약조성물
WO2003002978A2 (en) * 2001-06-27 2003-01-09 Surromed, Inc. Directed enzymatic modification of analytes for affinity capture and analysis
KR100517056B1 (ko) * 2002-04-15 2005-09-27 재단법인 목암생명공학연구소 하이드록실 페닐 유도체, 그의 제조방법 및 그를 포함하는약학적 조성물
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
CA2531692A1 (en) * 2003-07-07 2005-01-27 Fox Chase Cancer Center Hexameric porphobilinogen synthase as a target for the development of antibiotics and herbicides
US8153410B2 (en) * 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) * 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
KR20050078743A (ko) * 2004-02-02 2005-08-08 재단법인 목암생명공학연구소 로즈마린산의 하이드록실페닐 유도체를 유효성분으로 하는항암용 약학 조성물
ITMI20041871A1 (it) * 2004-10-01 2005-01-01 Indena Spa Uso di santoreggia satureja montana o dei suoi estratti per la preparazione di medicamenti per il trattamento dell'eiaculazione precoce
US7513627B2 (en) * 2005-12-30 2009-04-07 Honeywell International Inc. Image projection system with vibration compensation
CN100414293C (zh) * 2006-01-16 2008-08-27 复旦大学附属华山医院 一种测定咪唑立宾血药浓度的方法
CN101919837B (zh) * 2006-06-29 2011-08-03 山东绿叶天然药物研究开发有限公司 迷迭香酸在制备治疗或预防肾纤维化的药物中的应用
CN101095668B (zh) * 2006-06-29 2010-09-08 山东绿叶天然药物研究开发有限公司 迷迭香酸在制备治疗或预防肝纤维化和肾纤维化的药物中的应用
JP5372358B2 (ja) * 2007-01-20 2013-12-18 美智士 谷 生体活性治療物質
BRPI0802688C1 (pt) * 2008-06-25 2021-05-25 Acef S/A processo de obtenção de extrato rico em ácido rosmarínico (ar) obtido da espécie vegetal origanum vulgare e uso do extrato obtido
FR2948567B1 (fr) * 2009-07-31 2017-11-03 Inst De Rech Pour Le Dev Utilisation de l'acide rosmarinique et de ses derives pour traiter la ciguatera
CN102079705B (zh) * 2010-12-23 2013-03-13 济南九州富得香料有限责任公司 一种合成纯化脂溶性迷迭香酸酯的方法
CN102731296B (zh) * 2012-06-06 2015-06-10 中国人民解放军第二军医大学 迷迭香酸衍生物及其制备方法与在制备抗结核药物中的应用
US20140044813A1 (en) * 2012-08-09 2014-02-13 Kemin Industries, Inc. Plant Extracts for Improving Cognitive Health and Function
CN104744242B (zh) * 2013-12-25 2019-01-04 河北以岭医药研究院有限公司 一种（-）-丹参素钠的不对称合成方法及其应用
CN105997974A (zh) * 2016-07-19 2016-10-12 广西大学 迷迭香酸在制备治疗哮喘药物中的应用
CN110693873B (zh) * 2019-10-28 2022-07-12 杭州市西溪医院 冬凌草活性成分组合物的制备及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2952114C2 (de) * 1979-12-22 1984-01-05 A. Nattermann & Cie GmbH, 5000 Köln Verwendung von Rosmarinsäure bei der Bekämpfung von Entzündungen und hierbei eingesetzte Arzneimittel
DE2952115C2 (de) * 1979-12-22 1982-05-06 A. Nattermann & Cie GmbH, 5000 Köln Rosmarinsäure-Phospholipid-Komplex
DE3010040C2 (de) * 1980-03-15 1985-05-02 A. Nattermann & Cie GmbH, 5000 Köln Verfahren zur Gewinnung von Rosmarinsäure aus Melisse
JPH04243822A (ja) * 1991-01-24 1992-08-31 Tsumura & Co カルシウム拮抗剤
DE4121388A1 (de) * 1991-02-07 1992-08-13 Nattermann A & Cie Pharmazeutisches produkt zur behandlung von viruserkrankungen
CA2185983C (en) * 1996-09-19 2004-04-13 Wie-Jong Kwak Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition

Also Published As

Publication number Publication date
CN1219509C (zh) 2005-09-21
WO1999059606A1 (en) 1999-11-25
US6140363A (en) 2000-10-31
EP1077715A1 (de) 2001-02-28
JP2002526384A (ja) 2002-08-20
EP1077715B1 (de) 2006-03-29
DE69930619T2 (de) 2006-12-28
JP3827948B2 (ja) 2006-09-27
AU3734999A (en) 1999-12-06
CN1315863A (zh) 2001-10-03

Similar Documents

Publication Publication Date Title
DE69930619D1 (de) Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen
ATE198326T1 (de) Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
ATE256122T1 (de) Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate- aufnahme
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE69936352D1 (de) Stabilisierung von rapamycinen oder rapamycinderivaten
DE69629721D1 (de) Carnamoyloxy derivate von mutilin und deren verwendung als antibakterielles mittels
DE69836378D1 (de) 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren
DE59905858D1 (de) Verwendung von pit-emulsionen
ATE202347T1 (de) Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren
DE69621830T2 (de) Alpha-substituierte arylsulphonamidohydroxamsaüre als tnf-alpha und matrix-metalloproteinase-inhibitoren
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE69927128D1 (de) Verwendung von topisch applizierbaren Gerinnungsmaterial
DE69718791D1 (de) Neuartige aminosäurederivate und deren verwendung als thrombininhibitoren
DE69511240T2 (de) Derivate des hydroxamsäure als metalloproteinaseinhibitoren
DE59902868D1 (de) Verwendung von ectoin oder ectoin-derivaten in formulierungen
DE69807454T2 (de) Kosmetische oder dermatologische verwendung von 7-hydroxylierten steroiden
ATE229034T1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo- azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
ATE337845T1 (de) Verwendung von polymerisaten als filterhilfs- und/oder stabilisierungsmittel
ATE274024T1 (de) Sauerstoffabsorbierende zusammensetzung und ihre anwendungsmethode
ATE233542T1 (de) Verwendung von inhibitoren der retinosäureaktivität zur behandlung empfindlicher haut und/oder durch uv strahlung bewirkter akuter schädigungen
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
DE60005300D1 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
DE60100388D1 (de) Aminosäurederivate und deren verwendung als inhibitoren von nep, ace und ece

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee